PMV Pharmaceuticals, Inc. (PMVP): Total Liabilities
$11.85M
As of 2025-12-31
$10.57M
As of 2026-06-30
-21.3%
3-year compound annual growth
+13.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.85M | -22.1% | 2026-03-06, Balance as of period end |
| 2024-12-31 | $15.21M | -42.5% | 2026-03-06, Balance as of period end |
| 2023-12-31 | $26.46M | +9.0% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $24.28M | +5.5% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $23.01M | +259.0% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $6.41M | +40.1% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $4.57M | n/a | 2021-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $11.85M | -22.1% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $33.41M | +88.8% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $10.55M | +95.6% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $70.10M | +362.3% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $43.95M | +271.6% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $15.74M | +48.8% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $115.12M | -71.1% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $71.79M | +15.1% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $62.07M | -5.7% |
Compare PMVP, AVTX, AARD, CAMP side by side · Screen every company in Pharmaceutical Preparations ↗